Exploring Danaher – Balancing Technicals with Fundamentals

By Naomi Wentworth • Friday, July 25 09:59 • Permanent Link

Danaher logged a 0.4% change during today's morning session, and is now trading at a price of $203.65 per share. The S&P 500 index moved 0.0%. DHR's trading volume is 549,324 compared to the stock's average volume of 3,916,467.

Danaher trades -18.03% away from its average analyst target price of $248.46 per share. The 22 analysts following the stock have set target prices ranging from $205.0 to $310.0, and on average have given Danaher a rating of buy.

Anyone interested in buying DHR should be aware of the facts below:

Danaher's current price is 127.7% above its Graham number of $89.44, which implies that at its current valuation it does not offer a margin of safety
Danaher has moved -26.0% over the last year, and the S&P 500 logged a change of 16.6%
Based on its trailing earnings per share of 4.71, Danaher has a trailing 12 month Price to Earnings (P/E) ratio of 43.2 while the S&P 500 average is 29.3
DHR has a forward P/E ratio of 24.3 based on its forward 12 month price to earnings (EPS) of $8.38 per share
Its Price to Book (P/B) ratio is 2.79 compared to its sector average of 2.89
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Based in Washington, the company has 61,000 full time employees and a market cap of $145.82 Billion. Danaher currently returns an annual dividend yield of 0.6%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.